- Home
- NXC vs KPTI Comparison
NXC vs KPTI Comparison
Compare NXC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- KPTI
- Stock Information
- Founded
- NXC 1992
- KPTI 2008
- Country
- NXC United States
- KPTI United States
- Employees
- NXC N/A
- KPTI N/A
- Industry
- NXC Investment Managers
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- NXC Finance
- KPTI Health Care
- Exchange
- NXC Nasdaq
- KPTI Nasdaq
- Market Cap
- NXC 82.6M
- KPTI 81.1M
- IPO Year
- NXC N/A
- KPTI 2013
- Fundamental
- Price
- NXC $13.10
- KPTI $0.60
- Analyst Decision
- NXC
- KPTI Strong Buy
- Analyst Count
- NXC 0
- KPTI 4
- Target Price
- NXC N/A
- KPTI $5.00
- AVG Volume (30 Days)
- NXC 17.5K
- KPTI 840.0K
- Earning Date
- NXC 01-01-0001
- KPTI 02-19-2025
- Dividend Yield
- NXC 3.97%
- KPTI N/A
- EPS Growth
- NXC N/A
- KPTI N/A
- EPS
- NXC 0.19
- KPTI N/A
- Revenue
- NXC N/A
- KPTI $145,237,000.00
- Revenue This Year
- NXC N/A
- KPTI $4.47
- Revenue Next Year
- NXC N/A
- KPTI $7.35
- P/E Ratio
- NXC $70.47
- KPTI N/A
- Revenue Growth
- NXC N/A
- KPTI N/A
- 52 Week Low
- NXC $11.86
- KPTI $0.53
- 52 Week High
- NXC $13.70
- KPTI $1.70
- Technical
- Relative Strength Index (RSI)
- NXC 48.44
- KPTI 41.56
- Support Level
- NXC $13.00
- KPTI $0.53
- Resistance Level
- NXC $13.19
- KPTI $0.64
- Average True Range (ATR)
- NXC 0.09
- KPTI 0.05
- MACD
- NXC -0.00
- KPTI -0.00
- Stochastic Oscillator
- NXC 25.64
- KPTI 44.13
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.